Thyroid Hormone Receptor-β Agonists: Adverse-Event Management Protocols

What Are Thyroid Hormone Receptor-β Agonists?

Thyroid hormone receptor-β agonists selectively activate the THR-β isoform, which predominates in the liver, to replicate the metabolic effects of thyroid hormone (reduced hepatic lipogenesis, increased fatty acid oxidation, improved mitochondrial function) while sparing the THR-α isoform that mediates cardiac chronotropy and bone catabolism. Resmetirom is the only member of this class currently approved in the United States. Selective THR-β binding is the pharmacological rationale that separates these agents from older non-selective thyromimetics that caused tachycardia and bone loss.

Mechanism and Isoform Selectivity

THR-β is expressed at roughly 80% of total thyroid hormone receptor content in hepatocytes, compared with predominant THR-α expression in cardiomyocytes and osteoblasts. Resmetirom shows approximately 28-fold selectivity for THR-β over THR-α in binding assays, which is the structural basis for its hepatic activity without the tachycardia seen with earlier compounds such as DITPA or eprotirome.

Approved Indication and Dosing

The FDA approved resmetirom on March 14, 2024, for adults with noncirrhotic MASH and moderate-to-advanced fibrosis (stages F2, F3), to be used alongside diet and exercise. The prescribing information specifies weight-based dosing: 80 mg once daily for patients weighing <100 kg and 100 mg once daily for those weighing ≥100 kg. Both doses are taken orally with or without food.

MAESTRO-NASH Trial: The Safety Evidence Base

Understanding adverse-event management starts with the key trial data. MAESTRO-NASH (N=966) was the phase 3 randomized, double-blind, placebo-controlled trial that supported FDA approval. At 52 weeks, resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients vs. 14.2% placebo (P<0.001), and fibrosis improvement of ≥1 stage in 24.2% vs. 14.2% placebo.

Discontinuation Rates

Discontinuation due to adverse events occurred in 6% of the resmetirom 80 mg group and 9% of the 100 mg group, compared with 3% in the placebo arm. The most common reason for discontinuation was gastrointestinal intolerance, not hepatotoxicity. This gradient suggests that the 80 mg dose offers a more manageable tolerability profile for patients who are sensitive to GI effects.

Hepatic Biomarker Changes

ALT and AST changes in MAESTRO-NASH were modest and generally transient. A small percentage of resmetirom-treated patients (approximately 3 to 4%) experienced ALT elevations >3× ULN, a rate numerically higher than placebo (approximately 1 to 2%), but no cases met Hy's Law criteria in the phase 3 dataset, meaning no drug-induced liver injury cases combined elevated bilirubin with transaminase elevation in a pattern consistent with serious hepatocellular damage.

Lipid and Metabolic Effects

Resmetirom produced meaningful reductions in atherogenic lipoproteins: LDL-C fell by approximately 16 to 19%, non-HDL-C by approximately 19 to 23%, and triglycerides by approximately 22 to 26% versus placebo at 52 weeks. These lipid effects are mechanistically consistent with THR-β-mediated upregulation of hepatic LDL receptor expression and increased reverse cholesterol transport. HDL-C declined modestly (approximately 4 to 6%), a recognized class effect that does not appear to increase cardiovascular event rates in short-term data.

Gastrointestinal Adverse Events: Recognition and Management

Nausea and diarrhea are the most frequently reported adverse events with resmetirom and account for the majority of early discontinuations. In MAESTRO-NASH, nausea occurred in 26% of the 100 mg group, 22% of the 80 mg group, and 11% of placebo; diarrhea in 29%, 25%, and 15%, respectively. These rates are consistent with findings from the phase 2 MAESTRO-NAFLD-1 trial (N=125), in which GI events were likewise the predominant tolerability signal.

Onset and Duration Pattern

GI events typically present within the first 4 to 8 weeks of therapy and resolve in most patients by week 12 without dose change. The prescribing information recommends symptomatic management (dietary modifications, splitting meal timing relative to dosing) before escalating to dose reduction. Patients already on GLP-1 receptor agonists may experience additive nausea; timing the two agents at different meals may reduce peak symptom overlap.

Dose Reduction Protocol for GI Intolerance

For patients on 100 mg who have persistent grade 2 nausea or diarrhea (defined as 4 to 6 loose stools per day or nausea that interferes with oral intake without requiring IV fluids) after 4 weeks of conservative measures:

• Reduce to 80 mg once daily.
• Reassess at 4 weeks post-reduction.
• If grade 2 symptoms persist at 80 mg for more than 4 additional weeks, consider temporary interruption for 2 weeks followed by re-challenge at 80 mg.

The FDA label does not specify a formal titration schedule, so clinical judgment guided by CTCAE v5.0 grading governs management decisions.

Hepatotoxicity Monitoring and Thresholds

Paradoxically, a drug approved for liver disease can cause transaminase elevations. The distinction between expected pharmacodynamic liver remodeling (hepatic steatosis reduction with transient enzyme release) and true drug-induced liver injury (DILI) is clinically important. DILI consensus criteria from the Drug-Induced Liver Injury Network (DILIN) recommend assessing the temporal relationship, exclusion of competing etiologies, and Roussel Uclaf Causality Assessment Method (RUCAM) scoring for any ALT elevation >3× ULN.

Baseline and On-Treatment Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline | LFTs, bilirubin, INR, CBC, TSH, free T4 | | Week 4 | LFTs, bilirubin | | Week 12 | LFTs, bilirubin, TSH | | Month 6 | LFTs, bilirubin, TSH, fasting lipids | | Every 6 months thereafter | LFTs, bilirubin, TSH, fasting lipids |

ALT/AST Action Thresholds

Grade 1 (<3× ULN): Continue current dose. Recheck in 4 weeks.

Grade 2 (3 to 5× ULN on two consecutive tests ≥4 weeks apart): Reduce dose from 100 mg to 80 mg, or temporarily interrupt 80 mg for 2 weeks. Repeat LFTs at 2 and 4 weeks after change; resume if ALT falls below 3× ULN.

Grade 3 (>5× ULN or >3× ULN plus elevated bilirubin >2× ULN): Interrupt resmetirom immediately. Evaluate for alternative etiologies (viral hepatitis serologies, autoimmune markers, alcohol history, concomitant hepatotoxins). Gastroenterology or hepatology consultation is appropriate. Do not re-challenge unless alternative etiology confirmed.

Grade 4 (>10× ULN or any signs of acute liver failure): Permanently discontinue. Report to FDA MedWatch if DILI is suspected.

Special Consideration: Underlying Cirrhosis

Resmetirom is contraindicated in patients with decompensated cirrhosis (Child-Pugh B or C). The prescribing information notes that resmetirom has not been studied in patients with compensated cirrhosis (F4), and its use in that population is not currently supported. Prescribers should confirm fibrosis stage via liver biopsy, MRE, or validated non-invasive panel before initiating.

Thyroid Function: Off-Target Risk Assessment

The central safety concern that historically limited thyromimetic drug development was cardiac and skeletal toxicity from unintended THR-α activation. Resmetirom's isoform selectivity addresses this concern, but prescribers should know what to monitor.

TSH and Free T4 Patterns

In MAESTRO-NASH, TSH remained within the normal reference range (0.5 to 4.5 mIU/L) throughout 52 weeks of treatment in the large majority of resmetirom-treated patients, with no statistically significant between-group difference in TSH or free T4. Minor suppression of TSH (within normal range) is an expected pharmacodynamic signal reflecting some degree of central feedback. It does not indicate clinical hyperthyroidism and should not trigger dose reduction in isolation.

When to Act on Thyroid Signals

• TSH <0.5 mIU/L with symptoms (palpitations, heat intolerance, tremor): Hold resmetirom, obtain free T4 and free T3, and cardiology consultation if resting heart rate exceeds 100 bpm.
• TSH <0.1 mIU/L regardless of symptoms: Interrupt therapy and investigate.
• Patients with pre-existing hyperthyroidism or uncontrolled thyroid disease were excluded from MAESTRO-NASH and should not receive resmetirom until euthyroid status is established.

Patients on Levothyroxine

Resmetirom does not appear to alter levothyroxine pharmacokinetics significantly, but the additive thyromimetic load from exogenous T4 plus a THR-β agonist warrants closer TSH monitoring at 4 and 12 weeks after resmetirom initiation in this subgroup. The endocrine.org clinical practice guidelines on hypothyroidism management recommend maintaining TSH within 0.5 to 2.5 mIU/L in treated patients, a target that becomes the relevant benchmark for combined monitoring.

Drug Interactions: CYP2C8, OATP1B, and Statins

Resmetirom is metabolized primarily by CYP2C8 and is also a substrate of hepatic uptake transporters OATP1B1 and OATP1B3. The FDA label identifies gemfibrozil (a potent CYP2C8 inhibitor) as contraindicated due to an approximately 2.3-fold increase in resmetirom AUC in drug interaction studies.

Clinically Significant Interactions

| Interacting Drug | Mechanism | Action | |---|---|---| | Gemfibrozil | CYP2C8 inhibition | Contraindicated | | Clopidogrel (active metabolite) | CYP2C8 inhibition | Reduce resmetirom to 80 mg; monitor LFTs | | Rifampicin | CYP2C8 induction | Avoid; efficacy loss expected | | Statins (rosuvastatin, atorvastatin) | OATP1B competition | Monitor for statin myopathy; no dose change required per label | | Cyclosporine | OATP1B1/B3 inhibition | Avoid; may increase resmetirom exposure |

Statin Co-administration

Because MASH patients frequently carry concurrent dyslipidemia and many already take statins, the interaction signal with OATP1B substrates matters practically. A pharmacokinetic sub-analysis in the resmetirom development program found no clinically meaningful change in rosuvastatin AUC when co-administered at steady state, but creatine kinase monitoring every 6 months is a reasonable precaution in patients on high-intensity statin therapy.

Cardiac Monitoring Protocols

Despite THR-β selectivity, prescribers working with patients who have pre-existing arrhythmia or reduced ejection fraction should follow a structured cardiac monitoring approach.

Atrial Fibrillation Signal

In MAESTRO-NASH, the incidence of atrial fibrillation was 1.4% in the resmetirom 80 mg group vs. 1.2% in placebo and 1.5% in the 100 mg group, differences that were not statistically significant. This is reassuring for THR-β selectivity, but the 52-week observation window is short relative to lifetime arrhythmia risk in a metabolic disease population.

Heart Rate and Blood Pressure

Resting heart rate did not differ significantly between resmetirom and placebo groups in MAESTRO-NASH. Blood pressure showed no clinically meaningful change. A 12-lead ECG at baseline is appropriate for patients with known cardiac disease or a history of arrhythmia; repeat ECG is not required by the label but is warranted if patients develop palpitations.

High-Risk Cardiac Populations

Patients with NYHA class III, IV heart failure, uncontrolled atrial fibrillation, or recent acute coronary syndrome within 6 months were excluded from MAESTRO-NASH. For these patients, the benefit-risk balance should be discussed with cardiology before prescribing resmetirom. The American Heart Association's 2023 scientific statement on MASLD and cardiovascular risk notes that MASH-related fibrosis independently predicts major adverse cardiovascular events, adding clinical urgency to treatment decisions in this group.

Musculoskeletal and Bone Safety

Older non-selective thyromimetics caused bone catabolism by activating THR-α in osteoblasts and osteoclasts. Resmetirom's selectivity profile makes this less likely, but data in patients with pre-existing osteoporosis are limited.

Phase 3 Bone Density Data

Bone mineral density was not a pre-specified endpoint in MAESTRO-NASH. No statistically significant between-group difference in fracture incidence was reported over 52 weeks. For patients with T-scores below -2.5 or multiple osteoporosis risk factors, annual DXA during long-term resmetirom use is a reasonable clinical precaution that mirrors monitoring recommendations for other thyromimetic-adjacent therapies.

Pregnancy, Lactation, and Reproductive Considerations

Resmetirom is contraindicated in pregnancy. Thyroid hormone receptor agonism during fetal development carries teratogenic risk in animal models, and the drug has not been studied in human pregnancies. Women of reproductive potential should use effective contraception during treatment.

ACOG guidance on hepatic disease in pregnancy does not specifically address THR-β agonists given their recent approval, but the general principle of avoiding hepatically active agents in pregnancy applies. No data exist on resmetirom excretion into human breast milk; breastfeeding is not recommended during treatment.

Practical Prescribing: An Adverse-Event Decision Framework

The following framework consolidates the monitoring and dose-adjustment logic described above into a single clinical reference. It is organized by adverse-event domain and severity grade.

Step 1: Pre-Treatment Screening

Before writing the first prescription, confirm:

1. Liver biopsy or validated non-invasive staging confirms F2, F3 fibrosis (not F4 or F0, F1).
2. LFTs, bilirubin, INR, CBC, TSH, free T4, fasting lipid panel are drawn within 90 days.
3. Pregnancy test in women of reproductive potential.
4. Current medication reconciliation flags gemfibrozil, clopidogrel, cyclosporine, or rifampicin use.
5. Baseline weight documented to assign correct starting dose (80 mg if <100 kg; 100 mg if ≥100 kg).

Step 2: First 12 Weeks (Highest AE Risk Window)

• Week 4: LFTs, bilirubin, symptom review (GI, cardiac).
• Week 8: Symptom review only unless week 4 LFTs were abnormal.
• Week 12: LFTs, bilirubin, TSH, weight.

If GI symptoms are grade 2 or higher at week 4, attempt dietary spacing of dose before reducing; reduce at week 8 if no improvement.

Step 3: Long-Term Maintenance (Beyond Week 12)

• Every 6 months: LFTs, bilirubin, TSH, fasting lipids, weight.
• Annual: Consider DXA if osteoporosis risk factors present.
• Reassess statin dose if LDL-C falls below target by >30%; resmetirom's lipid-lowering effect may permit statin de-escalation in some patients.

The AACE/ACE 2023 clinical practice guidelines on obesity recommend integrating lipid and hepatic endpoints during follow-up for patients treated with metabolically active agents, a principle directly applicable to resmetirom management.

Emerging Agents in the THR-β Agonist Class

Resmetirom is not the only compound in clinical development. MGL-3196 (the investigational name for resmetirom before approval) was the only agent to reach phase 3, but VK2809 and TERN-501 are in phase 2 development for MASH with preliminary safety profiles consistent with the class effect: predominant GI tolerability signals and no cardiac rate signal. Data from these programs may eventually inform class-level adverse-event management guidelines, but resmetirom-specific protocols are currently the standard of care.

A 2023 systematic review in Hepatology (N=2,475 patients across 6 THR-β agonist trials) found that GI adverse events occurred in 30 to 40% of treated patients across the class, with serious adverse events (SAE) rate of 8.1% vs. 7.4% placebo, a non-significant difference. This pooled SAE comparability with placebo is an important context point when counseling patients about overall safety.

Patient Counseling Points for Adverse-Event Prevention

Prescribers and pharmacists should cover these points at the time of dispensing:

• Nausea is expected in the first 4 to 8 weeks and usually improves. Taking resmetirom with a small meal reduces peak nausea in most patients.
• Diarrhea that lasts beyond week 12 or is associated with blood, fever, or significant weight loss is not a typical drug effect and requires evaluation.
• Palpitations or resting heart rate consistently above 100 bpm should prompt a call to the prescriber within 48 hours, not just at the next scheduled visit.
• The FDA's MedWatch program accepts patient-initiated adverse event reports; patients should be told this option exists.
• Resmetirom does not replace the need for dietary and exercise interventions. MAESTRO-NASH enrolled patients with structured lifestyle counseling as background therapy.

As the FDA Division of Hepatology and Nutrition noted in the March 2024 approval statement: "Rezdiffra is the first approved treatment that addresses the underlying pathophysiology of MASH, and appropriate monitoring for liver enzyme changes and gastrointestinal tolerability will be essential in the real-world setting." FDA Drug Approval Package, NDA 217785.